Literature DB >> 23765802

Kaposi sarcoma herpesvirus/human herpesvirus-8-negative effusion-based lymphoma: report of 3 cases and review of the literature.

Jingnan Xiao1, Suzanne M Selvaggi, Catherine P Leith, Sean A Fitzgerald, Jimmie Stewart.   

Abstract

BACKGROUND: Primary effusion lymphoma (PEL) is a rare subtype of large B-cell lymphoma that arises in body cavities without detectable tumor masses. PEL is universally associated with Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus-8 (HHV8). Despite overlapping features, KSHV/HHV8-negative effusion-based lymphoma is a distinct entity from PEL. To date, 52 cases have been reported. The authors report 3 additional cases received in their laboratory from 2007 to 2012.
METHODS: Clinical data, cytomorphologic features, and immunophenotypic features of the 3 cases were described and compared with those reported in the literature.
RESULTS: The cells in HHV8-negative effusion lymphoma commonly revealed large cell, immunoblastic morphology and B-cell immunophenotype. The 3 cases demonstrated cytomorphologic and immunophenotypic variability. Cytomorphologically, 1 case contained large, highly atypical cells with a moderate amount of cytoplasm, round nucleus, coarsely granular chromatin, and a single macronucleolus. The other 2 cases had medium to large atypical cells with high nuclear-to-cytoplasmic ratios, slightly irregular to cleaved nuclei, and multiple conspicuous nucleoli. One case had a null phenotype with aberrant cytokeratin expression. B-cell phenotype was established by clonal immunoglobulin heavy-chain rearrangement using polymerase chain reaction, whereas the other 2 cases demonstrated a B-cell phenotype by flow cytometry and immunohistochemical staining. All 3 cases were negative for both HHV8 and Epstein-Barr virus.
CONCLUSIONS: HHV8-negative effusion lymphoma exhibits clinical, cytomorphologic, and immunophenotypic variability. Cases with a null-phenotype can be particularly challenging. When effusion lymphoma is suspected, ancillary tests are helpful. Moreover, HHV8 detection is critical in differentiating PEL and HHV8-negative effusion lymphoma, because they have overlapping features yet different prognoses.
© 2013 American Cancer Society.

Entities:  

Keywords:  Kaposi sarcoma herpesvirus/human herpesvirus-8; effusion lymphoma; pericardial effusion; pleural effusion; primary effusion lymphoma

Mesh:

Year:  2013        PMID: 23765802     DOI: 10.1002/cncy.21311

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  5 in total

1.  Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma.

Authors:  Matias Mendeville; Margaretha G M Roemer; Mari F C M van den Hout; G Tjitske Los-de Vries; Reno Bladergroen; Phylicia Stathi; Nathalie J Hijmering; Andreas Rosenwald; Bauke Ylstra; Daphne de Jong
Journal:  Blood       Date:  2018-12-03       Impact factor: 22.113

Review 2.  Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.

Authors:  Savanah D Gisriel; Ji Yuan; Ryan C Braunberger; Danielle L V Maracaja; Xueyan Chen; Xiaojun Wu; Jenna McCracken; Mingyi Chen; Yi Xie; Laura E Brown; Peng Li; Yi Zhou; Tarsheen Sethi; Austin McHenry; Ronald G Hauser; Nathan Paulson; Haiming Tang; Eric D Hsi; Endi Wang; Qian-Yun Zhang; Ken H Young; Mina L Xu; Zenggang Pan
Journal:  Mod Pathol       Date:  2022-05-13       Impact factor: 8.209

Review 3.  How do viruses trick B cells into becoming lymphomas?

Authors:  Ethel Cesarman
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

4.  Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis.

Authors:  Justin J Kuhlman; Muhamad Alhaj Moustafa; Alexander J Tun; David M Menke; Han W Tun; Liuyan Jiang
Journal:  Clin Case Rep       Date:  2021-04-04

Review 5.  Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV.

Authors:  Chih-Yi Liu; Bo-Jung Chen; Shih-Sung Chuang
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.